Optinose, INC DEF 14A proxy statements

OptiNose provides supplemental disclosures to its definitive proxy statement related to its merger with Paratek Pharmaceuticals in response to stockholder litigation alleging misrepresentations.

OptiNose addresses employee concerns regarding pay, benefits, and job security following the pending merger with Paratek Pharmaceuticals.

OptiNose and Paratek provide an update on integration planning following their executive leadership meeting, anticipating the merger to close around May 21, 2025, pending shareholder approval and regulatory clearances.

OptiNose, Inc. has scheduled a special meeting on May 16, 2025, for shareholders to vote on the proposed merger with Paratek Pharmaceuticals, Inc.

OptiNose, Inc. has scheduled a special meeting for stockholders to vote on the proposed merger agreement with Paratek Pharmaceuticals, Inc., where stockholders will receive $9.00 per share in cash and a contingent value right (CVR) representing the right to receive up to $5.00 in contingent cash payments.

OptiNose and Paratek Pharmaceuticals have entered into a merger agreement where Paratek will acquire OptiNose for a potential value of $330 million, pending shareholder approval and customary closing conditions.

OptiNose, Inc. has entered into a definitive agreement to be acquired by Paratek Pharmaceuticals, Inc. for $9.00 per share in cash plus one contingent value right (CVR) per share.

OptiNose, Inc. announces a definitive agreement to be acquired by Paratek Pharmaceuticals for $9 per share in cash, plus up to $5 per share in contingent value rights, potentially valuing the transaction at approximately $330 million.

Paratek Pharmaceuticals will acquire Optinose in a deal valued at up to $330 million, aiming to leverage Paratek's commercial infrastructure to broaden the reach of Optinose's XHANCE for chronic rhinosinusitis.

OptiNose is holding a special meeting to seek stockholder approval for a reverse stock split to increase its stock price and maintain its Nasdaq listing.

OptiNose is asking its stockholders to approve a reverse stock split to increase its stock price and maintain its Nasdaq listing.

OptiNose, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

OptiNose will hold its 2024 Annual Meeting of Stockholders on June 6, 2024, to vote on the election of directors, executive compensation, and the ratification of its accounting firm.